The spinout should give investors a percentage of new company. This is different than a spinoff, most likely this new company will work under SUPG roof. Orathecin gets a new life and my best guess is that the current shareholders will share 50-50 with this new venture. The capital will come from outside investors and SUPG needs to spell out such things as if this will be listed company. I would think it would take 25M to start up this venture, so as investors we are putting up our half with these assets of SUPG. If the price per share is 10.00, there would be 2.5m shares on the equity side and 2.5m shares divide by 57M outstanding shares. As SUPG investors we would get a little over 4% of our current position. So if you own 10k shares of supg you would get 400 shares of the new company at about 10.00 a share price. This would equate out to $4,000.00 valuation which is tax free until you sell it. Your basis in this would be zero.
I maybe way off here but it was a attempt to show, how it might work.